Evidence map›Paper›PMID 39462643›Full record

ArticleAlcohol, clinical & experimental research2024

From detection to intervention, optimizing care for patients with alcohol use disorder and advanced hepatic fibrosis.

Paola Zuluaga, Suthat Liangpunsakul

Abstract read
In one paragraph

Article in Alcohol, clinical & experimental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paola ZuluagaUniversitat Autònoma de Barcelona, Bellaterra, Spain.ORCID https://orcid.org/0000-0002-0247-0351
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine and Biochemistry, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-6504-8123

Funding

FKBP5 in the pathogenesis of alcohol-associated liver diseaseR01AA030312 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI Suthat Liangpunsakul · 2022 to 2026
$1.8M
Immunological Profiles and prognostic outcomes in patients with alcoholic hepatitisU01AA026917 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2022
$1.2M
Novel animal models to study miRNA-mediated alcoholic liver diseaseUH3AA026903 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2020 to 2022
$1.2M
Mechanism of PDK4 and MAM axis in alcohol-associated liver diseaseI01BX006202 · VA · RLR VA MEDICAL CENTER · PI Suthat Liangpunsakul · 2024 to 2026
–
Serum Proteomic Profiles as Biomarkers of Abusive Alcohol ConsumptionI01CX000361 · VA · RLR VA MEDICAL CENTER · PI LIANGPUNSAKUL, SUTHAT · 2012 to 2025
–
BLRD VA I01 BX006202Centres de Recerca de Catalunya 2021-SGR-00945CSRD VA I01 CX000361Instituto de Salud Carlos III JR20/00016Instituto de Salud Carlos III RD21/0009/0004NIAAA NIH HHS R01 AA030312NIAAA NIH HHS U01 AA026917NIAAA NIH HHS U01AA026917NIAAA NIH HHS UH3 AA026903NIAAA NIH HHS UH3AA026903School of Medicine, Indiana University Dean's ScholarU.S. Department of Veterans Affairs I01BX006202U.S. Department of Veterans Affairs I01CX000361
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39462643
PMCPMC11629437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.